Evaluating the role of active TGF-β1 as inflammatory biomarker in Kashmiri (North-Indian) patients with systemic sclerosis: a case-control study

Background As a master immune system regulator, transforming growth factor beta 1 (TGF-beta 1) is closely linked to the complicated pathophysiology and development of systemic sclerosis (SSc), a multisystem fibrotic disease. Objective We aim to evaluate the transcriptional levels of TGF-beta 1 mRNA in PBMCs, assess the TGF-beta 1 serum levels of SSc patients, and compare them with those of healthy subjects. Methods PBMCs were isolated from whole blood of 50 SSc patients and in 30 healthy controls. After total RNA was extracted from isolated PBMCs, complementary DNA (cDNA) synthesis was performed. Afterward, the expression of TGF-beta 1 mRNA was assessed using quantitative real-time PCR using the SYBR Green, GAPDH, and TGF-beta 1 specific primers. The serum levels of TGF-beta 1 were determined using a commercially available ELISA kit. Results There was a significant upregulation of TGF-beta 1 relative expression (p < 0.0001), when SSc patients were compared to the control group. The diffuse subgroup was more common in patients with elevated TGF-beta 1 mRNA expression (p < 0.0001). However, an insignificant difference was observed between the disease subsets of SSc. Serum TGF- beta 1 levels were upregulated in SSc patients (78.35 +/- 23.16) compared to healthy subjects (61.06 +/- 15.90), and were considerably higher in SSc patients with ILD (p < 0.01) and positive anti-topo-Isomerase antibody (p < 0.0001). Conclusion In patients with SSc, elevated levels of TGF-beta 1 in serum and their correlation with clinical symptoms imply that this cytokine may serve as a marker for fibrotic and vascular involvement in SSc.